CMS officials said Thursday (Oct. 6) that Medicare drug inflation rebates are calculated on price hikes in both the commercial and Medicare markets, confusing lobbyists who thought that measure was stripped during the budget resolution process. The Council for Informed Drug Spending Analysis estimates the commercial market spillover from Medicare rebates will reduce employer insurance costs by $31 billion from 2023 through 2031, including a $24 billion reduction in premiums paid by employers, and reduce employee out-of-pocket premiums and cost-sharing...